THE VALUE OF LDL-CHOLESTEROL AND HBA1C IN PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER ACUTE CORONARY SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AT TAM DUC HEART HOSPITAL

Thảo Nguyễn Sĩ Phương, Thảo Phan Thái

Main Article Content

Abstract

Background: LDL-cholesterol (LDL-C) plays a key role in the pathogenesis of coronary artery disease. In type 2 diabetes (T2D) patients, the disease tends to progress earlier and more severely, increasing the risk of major adverse cardiovascular events (MACEs). Objective: To evaluate the impact of LDL-C and glycemic control on MACEs after acute coronary syndrome (ACS) in patients with T2D. Methods: A retrospective cohort study was conducted on T2D patients hospitalized with ACS at Tam Duc Heart Hospital, Ho Chi Minh City, from January 1, 2021, to December 31, 2021. Results: A total of 177 patients were analyzed. After one year, 10 patients (5.6%) experienced MACEs. Only 24.9% achieved the LDL-cholesterol target and 20.3% achieved the HbA1C target. Patients who experienced MACEs had significantly higher HbA1C levels than event-free patients (p = 0.013). Although target attainment for LDL-C and HbA1C did not differ significantly between groups, the proportion with HbA1C > 8% was higher among those with MACEs (p = 0.041). Cox regression identified age and HbA1C > 8% as independent predictors of MACE (HR 4.657; 95% CI: 1.195–18.147; p = 0.027). Conclusion: Among T2D patients post-ACS, target attainment for LDL-C and HbA1C remained low. Age and HbA1C > 8% independently predicted MACEs, whereas LDL-C target attainment was not significantly associated with outcomes.

Article Details

References

1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
2. Casula M, Taietti I, Zeqaj I, et al. 386 Achieving Ldl Cholesterol Target In A Real-World Secondary Prevention Cohort: When Two Is Better Than One. European Heart Journal Supplements. 2020;22(Supplement_N):N132-N134. doi:10.1093/eurheartj/suaa207
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2019;41(1):111-188. doi:10.1093/ eurheartj/ehz455
4. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45(Supplement_1):S17-S38. doi:10.2337/dc22-S002
5. Arnott C, Li Q, Kang A, et al. Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2020;9(3):e014908. doi:doi:10.1161/JAHA.119.014908
6. Yang HP, Weng SJ, Ho ZP, Xu YY, Liu SC, Tsai YT. A Comparison of Rehospitalization Risks on Diabetic and Non-Diabetic Patients after Recovery from Acute Coronary Syndrome. Healthcare (Basel). May 28 2022;10(6)doi:10.3390/healthcare10061003
7. Qiu W, Chen J, Huang X, Guo J. The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study. Lipids Health Dis. Jul 6 2020;19(1):163. doi:10.1186/s12944-020-01340-5
8. Farkouh ME, Godoy LC, Brooks MM, et al. Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. J Am Coll Cardiol. Nov 10 2020; 76(19): 2197-2207. doi:10.1016/j.jacc.2020.09.536